CURRENT
ISSUE
1737

The FDA has approved acoltremon 0.003% ophthalmic solution (Tryptyr – Alcon) for treatment of dry eye disease. Acoltremon is the first transient receptor potential melastatin 8 (TRPM8) thermoreceptor agonist to be approved in the US for this indication.

DRY EYE DISEASE — Disruption of tear-film homeostasis (altered composition, reduced production, rapid evaporation) and resulting ocular surface inflammation cause the discomfort and blurred vision of dry eye disease. Many cases are caused by tear evaporation due to meibomian gland dysfunction. Other precipitating factors include...  Continue reading

Previous Issue: 1736
September 1, 2025
Coming Soon
Influenza Vaccine for 2025-2026
IV Meloxicam Returns for Treatment of Pain
Delgocitinib (Anzupgo) for Hand Eczema